[go: up one dir, main page]

DE69942925D1 - Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger. - Google Patents

Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger.

Info

Publication number
DE69942925D1
DE69942925D1 DE69942925T DE69942925T DE69942925D1 DE 69942925 D1 DE69942925 D1 DE 69942925D1 DE 69942925 T DE69942925 T DE 69942925T DE 69942925 T DE69942925 T DE 69942925T DE 69942925 D1 DE69942925 D1 DE 69942925D1
Authority
DE
Germany
Prior art keywords
cell
nucleic acid
acid molecule
antigen
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942925T
Other languages
English (en)
Inventor
Michael Hensel
Carlos Alberto Guzman
Eva Medina
Heiko Apfel
Christoph Hueck
David William Holden
Jacqueline Elizabeth Shea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development UK Ltd
Original Assignee
Emergent Product Development UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Development UK Ltd filed Critical Emergent Product Development UK Ltd
Application granted granted Critical
Publication of DE69942925D1 publication Critical patent/DE69942925D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69942925T 1998-09-04 1999-09-03 Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger. Expired - Lifetime DE69942925D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116827 1998-09-04

Publications (1)

Publication Number Publication Date
DE69942925D1 true DE69942925D1 (de) 2010-12-16

Family

ID=8232583

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69939264T Expired - Lifetime DE69939264D1 (de) 1998-09-04 1999-09-03 Attenuierte salmonella spi2 mutante als antigen-träger
DE69942925T Expired - Lifetime DE69942925D1 (de) 1998-09-04 1999-09-03 Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69939264T Expired - Lifetime DE69939264D1 (de) 1998-09-04 1999-09-03 Attenuierte salmonella spi2 mutante als antigen-träger

Country Status (13)

Country Link
US (3) US6936425B1 (de)
EP (2) EP1108034B1 (de)
JP (1) JP2002524077A (de)
AT (2) ATE486940T1 (de)
AU (1) AU5860599A (de)
BR (1) BR9914479A (de)
CA (1) CA2341349C (de)
CY (1) CY1109387T1 (de)
DE (2) DE69939264D1 (de)
DK (1) DK1108034T3 (de)
ES (2) ES2356863T3 (de)
PT (1) PT1108034E (de)
WO (1) WO2000014240A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711524C (en) 1994-12-09 2004-03-18 Emergent Product Development Uk Limited Identification of genes
CA2341349C (en) 1998-09-04 2013-12-10 Creatogen Aktiengesellschaft Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
AU2003204710B2 (en) * 1999-05-10 2006-08-03 Microscience Limited Attenuated microorganisms for the treatment of infection
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2001070247A2 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
EP1640013A3 (de) * 2000-03-17 2007-02-21 Pharmacia & Upjohn Company LLC Inaktivierte Salmonella Impfstoffe
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2002092814A2 (en) * 2001-05-17 2002-11-21 Creatogen Aktiengesellschaft Screening method for attenuating or virulence defective microbial cells
WO2006015445A1 (en) 2004-08-13 2006-02-16 Marshall Barry J Bacterial delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
EP2066339B1 (de) * 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008141226A2 (en) * 2007-05-10 2008-11-20 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US20110027321A1 (en) * 2007-05-25 2011-02-03 Emergent Product Development Gaithersburg Inc. Chlamydia Vaccine Comprising HtrA Polypeptides
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
NZ585776A (en) * 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
WO2009158240A1 (en) * 2008-06-16 2009-12-30 Emergent Product Development Uk Limited Salmonella vectored vaccines against chlamydia and methods of use
EP2318515A4 (de) 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd Impfstoffe gegen clostridium difficile und anwendungsverfahren
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
JP4575498B2 (ja) * 2009-02-20 2010-11-04 株式会社東芝 磁気記録媒体の製造方法
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
US8518658B1 (en) * 2009-04-27 2013-08-27 University Of South Florida ATP-bioluminescence immunoassay
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
EP2526185A4 (de) 2010-01-22 2013-07-24 Univ Arizona Bakterium mit einer regulierten rfah-nukleinsäure
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
ES2753142T3 (es) 2010-06-09 2020-04-07 Univ Arkansas Vacuna y métodos para reducir una infección por Campylobacter
US8481052B2 (en) * 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
RU2510839C2 (ru) * 2012-05-03 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Вакцина ассоциированная против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов
RU2496518C1 (ru) * 2012-05-03 2013-10-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Способ изготовления вакцины ассоциированной против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
JP6216371B2 (ja) * 2012-05-23 2017-10-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用
EP2895191B1 (de) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (de) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung der immunreaktionen gegen enterale pathogene
WO2014144965A1 (en) * 2013-03-15 2014-09-18 Husseiny Elsayed Mohamed I Attenuated salmonella bacteria and methods of using
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4045672A4 (de) * 2019-10-18 2023-11-22 University of Virginia Patent Foundation Zusammensetzungen und verfahren für die erzeugung verbesserter immunantworten und schnelle antikörperproduktion
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2022271976A1 (en) * 2021-06-24 2022-12-29 Elanco Us Inc. Attenuated salmonella, vaccines, and delivery platform
CN114292339B (zh) * 2022-01-05 2022-08-09 武汉科前生物股份有限公司 鞭毛素突变体与非洲猪瘟抗原的融合蛋白及其应用
CN114703214A (zh) * 2022-03-03 2022-07-05 南京吉芮康生物科技研究院有限公司 一种抗丢失时空可控表达的新型质粒及其应用
AU2023346467A1 (en) * 2022-09-21 2025-03-27 Prokarium Limited Salmonella strain with chromosomally integrated landing pad

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232165A (en) * 1880-09-14 Mechanical musical instrument
US1449502A (en) * 1921-04-23 1923-03-27 James G Diffendaffer Restraining device
US1476164A (en) * 1922-02-21 1923-12-04 Michael J Manahan Door and window shade and curtain clamp
US1903387A (en) * 1930-08-20 1933-04-04 Eaton Mfg Co Automobile heater
US2103863A (en) * 1936-12-28 1937-12-28 Woodall Industries Inc Visor construction
US2728467A (en) * 1954-01-28 1955-12-27 Glicker Herman Parking tower structure
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
NZ192465A (en) * 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) * 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) * 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
EP0669989A1 (de) 1991-08-22 1995-09-06 Washington University Polynukleotid-Sonden für Salmonella
WO1993007266A1 (en) 1991-10-07 1993-04-15 Idaho Research Foundation, Inc. Genetic construct for selection of homologous recombinants on a single selective medium
AU3130893A (en) 1991-11-15 1993-06-15 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
JPH08503136A (ja) 1992-11-06 1996-04-09 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ Ｐ．ｍｕｌｔｏｃｉｄａによるパスツレラ症に対する感染防御剤
WO1994026933A1 (en) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
AU711524C (en) * 1994-12-09 2004-03-18 Emergent Product Development Uk Limited Identification of genes
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
AU7738396A (en) 1995-11-14 1997-06-05 General Hospital Corporation, The Salmonella secreted proteins and uses thereof
US6030624A (en) 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998035562A1 (en) 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
CA2341349C (en) 1998-09-04 2013-12-10 Creatogen Aktiengesellschaft Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
CN1196787C (zh) * 1998-11-09 2005-04-13 微科学有限公司 毒力基因和蛋白质及其用途
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2001032697A2 (en) 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Virulence genes and proteins from brucella melitensis, and their use
JP2003520034A (ja) * 1999-12-23 2003-07-02 ヴィマックス リミテッド ビルレンス遺伝子、タンパク質、およびそれらの用途
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
JP2002524077A (ja) 2002-08-06
WO2000014240A3 (en) 2000-08-03
CA2341349A1 (en) 2000-03-16
EP1970449B1 (de) 2010-11-03
BR9914479A (pt) 2001-06-26
EP1108034B1 (de) 2008-08-06
AU5860599A (en) 2000-03-27
ES2356863T3 (es) 2011-04-13
ATE486940T1 (de) 2010-11-15
WO2000014240A2 (en) 2000-03-16
DE69939264D1 (de) 2008-09-18
US20080075739A1 (en) 2008-03-27
EP1108034A2 (de) 2001-06-20
CY1109387T1 (el) 2014-07-02
ATE403728T1 (de) 2008-08-15
CA2341349C (en) 2013-12-10
US20040203039A1 (en) 2004-10-14
PT1108034E (pt) 2008-11-14
US7955600B2 (en) 2011-06-07
US6936425B1 (en) 2005-08-30
EP1970449A1 (de) 2008-09-17
US7700104B2 (en) 2010-04-20
DK1108034T3 (da) 2008-11-10
ES2313792T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
DE69942925D1 (de) Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger.
Vemulapalli et al. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
KR937000640A (ko) 생 백신
NZ618298A (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
CY1107656T1 (el) Εξασθενημενοι μικροοργανισμοι για την αντιμετωπιση μολυνσης
NZ316787A (en) Methods and compositions for the selective modification of nucleic acids
ATE454163T1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
NO960839L (no) Bakterieeksporterte proteiner og acellulære vaksiner som er basert på disse
Vanloubbeeck et al. The immunology of Leishmania infection and the implications for vaccine development
WO1995003414A3 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
PT712926E (pt) Virus da doenca pancreatica do peixe
NO924576D0 (no) Kloning og ekspresjon av gener som koder for arabinan-nedbrytende enzymer av sopp-opprinnelse
DK0892054T3 (da) Clostridium perfringens-vaccine
ATE107516T1 (de) Pasteurella-impfstoff.
Davies et al. Comparison of outer-membrane proteins of Pasteurella haemolytica expressed in vitro and in vivo in cattle
Kamei et al. Induction of stress protein synthesis in Histoplasma capsulatum by heat, low pH and hydrogen peroxide
ATE181104T1 (de) Isoliertes pctd plasmid aus chlamydia trachomatis von serotyp d, dessen genen und davon kodierten proteine, rekombinante plasmide für die expression von deren genen als fusionsproteine in einem keterologen system, und ihre verwendung als impfstoff- und/oder diagnostiekformulierung
Ward et al. Antibody response to outer-membrane antigens of Pseudomonas aeruginosa in human burn wound infection
DE69941099D1 (de) Spezifische Nukleinsäuren und Polypeptide aus krankheitserregenden Stämmen von Neisseria
CA3205817A1 (en) Irradiated whole-cell immunogens of acinetobacter baumannii
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.
WO1996002272A3 (en) Treatment of autoimmune diseases
EA200000618A1 (ru) Вакцина для иммунизации позвоночных против заболеваний, вызываемых патогеном, вакцина для профилактики или лечения позвоночного от бруцеллеза, аттенюированный или авирулентный вариант штамма в. abortus rb51, способ профилактики или лечения позвоночного при риске заболевания или страдающего от патогенного микроорганизма (варианты), способ профилактики или лечения позвоночного при риске заболевания или страдающего от бруцеллеза